Entering text into the input field will update the search result below

KNCQF Kancera AB (publ)
Stock Price & Overview

Grey Market | $USD | N/A


Div Rate (TTM)
Yield (TTM)
Short Interest
Market Cap
Prev. Close

Quant Ranking

Company Profile

Kancera AB (publ) logo
Kancera AB (Publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops HDAC for the treatment of nerve inflammation and pain; and ROR1 inhibitors for the treatment of solid tumors and blood cancers. Kancera AB (Publ) was founded in 2010 and is based in Solna, Sweden.
  • Karolinska Institutet Science Park
  • Nanna Svartz Väg 4
  • Solna, 171 65
  • Sweden
Phone Number
46 8 50 12 60 80
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.